TY  - GEN 
AU  - Hernández-Boluda, J.C.
AU  - Pereira, A.
AU  - Pastor-Galán, I.
AU  - Alvarez-Larrán, A.
AU  - Savchuk, A.
AU  - Puerta, J.M.
AU  - Sánchez-Pina, J.M.
AU  - Collado, R.
AU  - Díaz-González, A.
AU  - Angona, A.
AU  - Sagüés, M.
AU  - García-Gutiérrez, V.
AU  - Boqué, C.
AU  - Osorio, S.
AU  - Vallansot, R.
AU  - Palomera, L.
AU  - Mendizábal, A.
AU  - Casado, L.F.
AU  - Pérez Encinas, Manuel Mateo
AU  - Pérez-López, R.
AU  - Ferrer-Marín, F.
AU  - Sánchez-Guijo, F.
AU  - García, C.
AU  - Heras, N.
AU  - López-Lorenzo, J.L.
AU  - Cervantes, F.
AU  - Steegmann, J.L.
PY  - 2018
SN  - 2044-5385
UR  - http://hdl.handle.net/20.500.11940/20387
AB  - Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but its...
LA  - eng
KW  - Aged
KW  - Anticarcinogenic Agents
KW  - Biomarkers
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Follow-Up Studies
KW  - Fusion Proteins, bcr-abl
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Protein Kinase Inhibitors
KW  - Recurrence
KW  - Treatment Outcome
TI  - Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
DO  - 10.1038/S41408-018-0125-0
KW  - AS Santiago AP
KW  - CHUS
VL  - 8
ER  -